JP2024535672A5 - - Google Patents
Info
- Publication number
- JP2024535672A5 JP2024535672A5 JP2024507845A JP2024507845A JP2024535672A5 JP 2024535672 A5 JP2024535672 A5 JP 2024535672A5 JP 2024507845 A JP2024507845 A JP 2024507845A JP 2024507845 A JP2024507845 A JP 2024507845A JP 2024535672 A5 JP2024535672 A5 JP 2024535672A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- endonuclease
- sequence
- nuclease system
- manipulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163241928P | 2021-09-08 | 2021-09-08 | |
| US63/241,928 | 2021-09-08 | ||
| PCT/US2022/075992 WO2023039378A1 (en) | 2021-09-08 | 2022-09-06 | Class ii, type v crispr systems |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024535672A JP2024535672A (ja) | 2024-10-02 |
| JP2024535672A5 true JP2024535672A5 (https=) | 2025-09-16 |
Family
ID=85506852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024507845A Pending JP2024535672A (ja) | 2021-09-08 | 2022-09-06 | クラスｉｉ、ｖ型ｃｒｉｓｐｒ系 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240336905A1 (https=) |
| EP (1) | EP4399305A4 (https=) |
| JP (1) | JP2024535672A (https=) |
| KR (1) | KR20240055073A (https=) |
| CN (1) | CN117999351A (https=) |
| AU (1) | AU2022342157A1 (https=) |
| CA (1) | CA3228222A1 (https=) |
| MX (1) | MX2024003007A (https=) |
| WO (1) | WO2023039378A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021178933A2 (en) | 2020-03-06 | 2021-09-10 | Metagenomi Ip Technologies, Llc | Class ii, type v crispr systems |
| WO2022240858A1 (en) | 2021-05-10 | 2022-11-17 | Mammoth Biosciences, Inc. | Effector proteins and methods of use |
| GB2625500B (en) | 2021-09-21 | 2026-04-01 | Scribe Therapeutics Inc | Engineered CasX repressor systems |
| US20230257739A1 (en) * | 2022-01-21 | 2023-08-17 | Mammoth Biosciences, Inc. | Effector proteins and methods of use |
| AU2023276763A1 (en) | 2022-05-25 | 2024-12-12 | Metagenomi Therapeutics, Inc. | Supplementation of liver enzyme expression |
| GB2634837A (en) | 2022-06-07 | 2025-04-23 | Scribe Therapeutics Inc | Compositions and methods for the targeting of PCSK9 |
| CN119403922A (zh) * | 2022-06-10 | 2025-02-07 | 拜耳公司 | 新的小型v型rna可编程内切核酸酶系统 |
| CN120712347A (zh) * | 2023-02-21 | 2025-09-26 | 中国农业大学 | CRISPR/Cas效应蛋白及系统 |
| WO2024187140A2 (en) * | 2023-03-08 | 2024-09-12 | Metagenomi, Inc. | Class 2, type v crispr systems |
| WO2024196741A2 (en) * | 2023-03-17 | 2024-09-26 | Mammoth Biosciences, Inc. | Crispr systems targeting the braf gene relating to the treatment of melanoma |
| WO2024196911A1 (en) * | 2023-03-20 | 2024-09-26 | Mammoth Biosciences, Inc. | Ultracompact precision editing systems and uses thereof |
| WO2024254519A2 (en) * | 2023-06-08 | 2024-12-12 | Mammoth Biosciences, Inc. | Compositions and methods for the modification of human genes expressed by liver cells |
| WO2025076084A1 (en) * | 2023-10-02 | 2025-04-10 | Acrigen Biosciences | Engineered nucleases and compositions and methods thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020123887A2 (en) * | 2018-12-14 | 2020-06-18 | Pioneer Hi-Bred International, Inc. | Novel crispr-cas systems for genome editing |
| JP2024509353A (ja) * | 2021-01-25 | 2024-03-01 | ザ・ブロード・インスティテュート・インコーポレイテッド | 再プログラム可能なＴｎｐＢポリペプチド及びその使用 |
| WO2023141590A2 (en) * | 2022-01-21 | 2023-07-27 | Mammoth Biosciences, Inc. | Effector proteins and methods of use |
| WO2023232109A1 (zh) * | 2022-06-01 | 2023-12-07 | 中国科学院遗传与发育生物学研究所 | 新的crispr基因编辑系统 |
| JP2025519628A (ja) * | 2022-06-10 | 2025-06-26 | アクリジェン バイオサイエンシーズ | 核酸改変のための組成物及び方法 |
-
2022
- 2022-09-06 JP JP2024507845A patent/JP2024535672A/ja active Pending
- 2022-09-06 AU AU2022342157A patent/AU2022342157A1/en active Pending
- 2022-09-06 WO PCT/US2022/075992 patent/WO2023039378A1/en not_active Ceased
- 2022-09-06 MX MX2024003007A patent/MX2024003007A/es unknown
- 2022-09-06 KR KR1020247011373A patent/KR20240055073A/ko active Pending
- 2022-09-06 CN CN202280060888.0A patent/CN117999351A/zh active Pending
- 2022-09-06 CA CA3228222A patent/CA3228222A1/en active Pending
- 2022-09-06 EP EP22868244.9A patent/EP4399305A4/en active Pending
-
2024
- 2024-03-06 US US18/597,260 patent/US20240336905A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024535672A5 (https=) | ||
| JP2022520428A5 (https=) | ||
| KR102168489B1 (ko) | CRISPR/Cpf1 시스템을 이용한 유전체 편집용 조성물 및 이의 용도 | |
| JP2023519953A5 (https=) | ||
| JP2023540797A5 (https=) | ||
| FI3765615T3 (fi) | Uusia DNA:han kohdentuvia CRISPR-entsyymejä ja järjestelmiä | |
| JP2023517041A5 (https=) | ||
| JP2022539338A5 (https=) | ||
| FI3802807T3 (fi) | Rna-ohjattuja nukleaaseja ja niiden aktiivisia fragmentteja ja variantteja ja menetelmiä niiden käyttämiseksi | |
| JP2025181841A5 (https=) | ||
| JP2022552409A5 (https=) | ||
| JP2025512996A (ja) | アデノシンデアミナーゼ、塩基エディター及び応用 | |
| US20170152508A1 (en) | Using Truncated Guide RNAs (tru-gRNAs) to Increase Specificity for RNA-Guided Genome Editing | |
| JP2024541402A5 (https=) | ||
| EP3341477A1 (en) | Engineered crispr-cas9 nucleases | |
| JP2022531347A5 (https=) | ||
| JP2024517607A5 (https=) | ||
| CN114144519B (zh) | 单碱基置换蛋白以及包含其的组合物 | |
| JP2024511163A5 (https=) | ||
| JP2024511131A5 (https=) | ||
| JP2024511621A5 (https=) | ||
| CA3163087A1 (en) | System and method for activating gene expression | |
| WO2023206872A1 (zh) | 一种工程优化的核酸酶、向导rna、编辑系统和应用 | |
| WO2023098485A1 (zh) | 一种基于c2c9核酸酶的新型基因组编辑系统及其应用 | |
| JP2023529844A5 (https=) |